ipo - Search News

Venture Global’s Stumble Reflects Chilly State of IPO Market

Hosted on MSN · 3h

Venture Global trades below IPO price in disappointing debut despite Trump's support of LNG industry

"The Trump administration has made very clear they support growing LNG exports," Venture CEO Mike Sabel told CNBC in an interview Friday.

MarketWatch on MSN · 2h

LNG exporter Venture Global dips below IPO price in its trading debut

The energy company raised $1.75 billion by pricing 70 million shares at $25, the middle of its reduced $23 to $27 price range.

Wall Street Journal · 3h

Venture Global’s Stumble Reflects Chilly State of the IPO Market

Venture Global launched its initial public offering with a lofty goal: Raise up to $2.3 billion at a $110 billion valuation in the biggest stock-market debut since summer. The market had different plans.

Ascentage Pharma, IPO

Bloomberg L.P. · 7h

Ascentage Pharma’s US Shares Climb After $126 Million IPO

Shares of Ascentage Pharma Group International rose as much as 4% in the Chinese biopharmaceutical company’s US trading debut after pricing its $126.4 million initial public offering at a discount to its Asian stock.

Investing.com on MSN · 6h

Ascentage Pharma IPO opens flat

IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The pharmaceutical company, already listed on the Main Board of the Stock Exchange of Hong Kong Limited under the code 6855.

Seeking Alpha on MSN · 8h

Takeda-backed Ascentage Pharma prices $126M U.S. IPO

Ascentage Pharma Group (AAPG) (AAPGV) (OTCPK:ASPHF), which is backed by Takeda (NYSE:TAK), has priced a $126M U.S. initial public offering. The China-based drug developer priced 7.33M shares at $17.25 per share,

11h

IPO market comeback: How recent major US listings fared

The U.S. IPO market is expected to see a blowout 2025, fueled by the return of business-friendly Donald Trump to the White ...

7h

3FPX, ARM : IPO Rebound In 2025? Here's What's Fueling The Boom,...

The year 2025 is expected to see a resurgence of IPOs due to policy changes, monetary easing, and a favorable business ...

FierceBiotech9h

‘A really rational IPO environment’: What does it takes for a biotech to go public now?

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

5h

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

1hon MSN

Denta Water and Infra IPO day 3: GMP, subscription status to review. Should you apply as bidding ends today?

According to market observers, shares of the company are available at a premium of ₹151 in the grey market today ...

16h

Trump Partner Builds $1 Billion Stake From India Real Estate IPO

When Donald Trump’s real estate business wanted to break into the Indian market in 2012, it turned to Atul Chordia and his ...

7h

2024 Year In Review: IPO Market Overview

In 2024, global and US markets saw a slight increase in IPOs. Syntax Data used its FIS classification system to analyze the ...

FierceBiotech14h

Obesity biotech Aardvark eyes IPO as Ascentage makes $126M Nasdaq debut

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results